Global Clinical Launch: HUTCHMED initiated the global Phase I clinical trial for HMPL-A251 on December 16, 2025, in China, aiming to evaluate the efficacy and safety against unresectable HER2-positive tumors, marking the first clinical application of its ATTC platform and potentially opening new market opportunities for the company.
Innovative Drug Mechanism: HMPL-A251 combines a highly selective PI3K/PIKK inhibitor with a humanized anti-HER2 antibody via a cleavable linker, designed to directly target tumor cells and overcome the systemic toxicity issues associated with traditional PI3K inhibitors, thereby enhancing tolerability and efficacy.
Clinical Study Design: The study is divided into a Phase I dose escalation and a Phase IIa expansion part, primarily assessing the safety and tolerability of HMPL-A251 to determine the maximum tolerated dose (MTD), laying the groundwork for subsequent Phase II and III studies, indicating its potential in cancer treatment.
Preclinical Data Support: Preclinical data for HMPL-A251 was presented at the 2025 AACR-NCI-EORTC International Conference, supporting its translational potential and signaling HUTCHMED's ongoing innovation and development in the field of precision oncology.
HCM
$13.26+Infinity%1D
Analyst Views on HCM
Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 19.38 USD with a low forecast of 13.75 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 19.38 USD with a low forecast of 13.75 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
1 Sell
Hold
Current: 13.190
Low
13.75
Averages
19.38
High
25.00
Current: 13.190
Low
13.75
Averages
19.38
High
25.00
Morgan Stanley
Equal Weight -> Underweight
downgrade
$18
2025-09-22
Reason
Morgan Stanley
Price Target
$18
2025-09-22
downgrade
Equal Weight -> Underweight
Reason
Morgan Stanley downgraded Hutchmed to Underweight from Equal Weight with a price target of $13.75, down from $18. The company reduced its commercial guidance amid a restructuring and its "lackluster" near-term growth could drive a valuation de-rating, the analyst tells investors in a research note. The firm says Hutchmed's approved assets could be entering a period of declining product life cycles and patent expirations.
BofA
Buy
upgrade
$27 -> $28
2025-07-22
Reason
BofA
Price Target
$27 -> $28
2025-07-22
upgrade
Buy
Reason
BofA raised the firm's price target on Hutchmed to $28 from $27 and keeps a Buy rating on the shares. The firm updated its model to include a revenue build for tazemetostat and adjust expectations slightly for operating expenses, the analyst tells investors in an earnings preview for its small-to-mid cap biotech coverage.
HSBC
Buy
to
Hold
downgrade
$14.70
2025-05-13
Reason
HSBC
Price Target
$14.70
2025-05-13
downgrade
Buy
to
Hold
Reason
HSBC downgraded Hutchmed to Hold from Buy with a $14.70 price target.
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
